The Minimalist Trial-2
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer. Oropharynx SCC (OPSCC) is a common sub-type of HNSCC. Each year, 16,000 new cases of OPSCC are diagnosed in the USA. Most cases of OPSCC (\>90%) are caused by the human papillomavirus (HPV) and are often cured with current therapy. However, patients treated with surgery followed by postoperative adjuvant chemotherapy and radiation therapy (POA(C)RT) still experience substantial morbidity. In this highly curable disease, current clinical research interest is focused on investigation of de-escalated therapy, with the goal to reduce treatment-related adverse events (AEs) while maintaining a low recurrence rate. In this study, patients with HPV-related OPSCC will undergo resection of the primary tumor site and involved/at-risk regional neck nodes. Based on the pathology report, patients will be assigned to: * Arm 1 (de-POACRT-42 Gy) * Arm 2A (de-POART-42 Gy) * Arm 2B (de-POART-37.8 Gy) * Arm 2C (de-POACRT-30 Gy). All patients with high-risk pathology will be assigned to Arm 1 whereas patients with intermediate-risk pathology will be randomized (1:1:1) to Arm 2A, Arm 2B, or Arm 2C. Patients with highest-risk pathology and low-risk pathology will be removed from the trial after surgery and will be advised to pursue standard of care options.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rak gardła związany z wirusem HPV, stadium 1-2
- •Планируется chirurgiczne usunięcie guza dostępem przez usta
- •Planowane usunięcie węzłów chłonnych na szyi
- •Ogólny stan zdrowia pozwalający na uczestnictwo (ECOG 0-2)
- •Prawidłowa funkcja nerek, białych krwinek i płytek krwi
- •Wiek co najmniej 18 lat
- •Zgoda na stosowanie antykoncepcji (dla kobiet w wieku rozrodczym i mężczyzn)
- •Podpisana świadoma zgoda na uczestnictwo w badaniu
✗ Disqualifies
- •Bardzo małe guzy (T1N0M0 lub T2N0M0)
- •Wcześniejsza radioterapia szyi lub głowy
- •Planowana rozległa rekonstrukcja po operacji
- •Ciężka choroba wątroby (marskość)
- •Wcześniejszy nowotwór w ciągu ostatnich 2 lat
- •Uczestnictwo w innym eksperymentalnym badaniu
- •Poważne problemy zdrowotne lub psychiczne uniemożliwiające uczestnictwo
- •Ciąża lub karmienie piersią
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 24, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (3)
Washington University School of Medicine
St Louis, United States
Sanford Roger Maris Cancer Center
Fargo, United States
Sanford Cancer Center
Sioux Falls, United States
Trial contact
Douglas Adkins, M.D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/26/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.